Stock Groups

Wouldn’t worry about monkeypox, cuts drug costs for low-income

[ad_1]

Albert Bourla (Pfizer CEO) at the WEF, Davos Switzerland, May 25, 2022.

Adam Galici | CNBC

PfizerOn Wednesday,’s CEO stated that he wouldn’t be concerned about recent cases of monkeypox that have been increasing in other countries.

CNBC’s Albert Bourla stated that the current evidence on the disease indicates that it does not transmit as easily to other viruses like Covid-19 and it is unlikely that it will lead to a pandemic.

“I don’t have all of the information I need.” He said that with all the information I have, I would not worry too much.” World Economic ForumDavos

He said, “That does not mean we should be relaxed.” “I believe we need to monitor the current situation.”

Monkeypox has been identified as a rare viral infection that is endemic to Central and West Africa. It can spread throughout the world. through close contact with people, animals or material infected with the virus, with symptoms including rashes, fever, headaches, muscle ache, swelling and backpain.

Although most cases are mild they can be severe. typically resolving within two to four weeksHealth experts are baffled at the sudden spike in patients from countries that have never been affected by the disease or those who do not know how to travel to countries endemic.

Effective Wednesday at least 237 confirmed and suspected cases of monkeypox had been reported in countries outside of Africa, including in the United Arab Emirates — the first gulf state to report a case.

Bourla said that existing treatment options offer reason to be hopeful. The effectiveness of smallpox vaccines against monkeypox has been proven to be 85%. France DenmarkTargeted vaccinations are being considered for people most susceptible to the disease.

The poorest nations in the world to get medicines at a reasonable price

Pfizer will include in its program “An agreement for a better world” 27 countries with low incomes and 18 other lower-income nations that cover most of Africa, Southeast Asia and the Middle East.

Xinhua News Agency | Xinhua News Agency | Getty Images

Pfizer stated that the program aims to increase access to essential medicines in poorer countries through ease and speed.

Bourla stated that the company has achieved the goal set by him in 2019 to reduce by 50% the global number of people who cannot afford medicine by 2023.

He said that “Today, we’re going to achieve it,” and that shareholders should “believe that we do the right thing.”

Covid-19 shortages being addressed

[ad_2]